Is Vir Biotechnology Inc (VIR) overvalued? · rev $74.2M
Vir Biotechnology Inc (VIR) is a biotechnology company listed on NASDAQ.
This page asks whether Vir Biotechnology Inc (VIR) looks expensive on cached numbers — not a short thesis.
Latest reported VIR revenue for 2024-12-31 was $74.2M. Net income was -$522.0M. Revenue was down 13.9% from 2023-12-31 to 2024-12-31. VIR currently screens at market cap $1.45B.
VIR currently screens at market cap $1.45B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VIR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VIR stock page for the full model, not this heading.
Not investment advice.